The Ebola Strain Nobody Has a Vaccine For Just Infected an American
An American doctor in Congo just tested positive for a strain of Ebola that has no approved vaccine and no proven treatment. Now the U.S. government and a handful of biotechs are in a dead sprint to build the countermeasures that should have existed years ago.
Imagine catching a disease that kills roughly one in three people who get it. Now imagine there's no approved vaccine and no proven treatment. That's the situation facing Dr. Peter Stafford, an American physician who tested positive for Bundibugyo ebolavirus while treating patients at Nyankunde Hospital in Bunia, a city in the Democratic Republic of Congo's embattled Ituri Province.
He's been medevaced to Germany. Six close contacts are being monitored. And the U.S. government just kicked its biodefense machine into high gear.
Not Your "Typical" Ebola
When most people hear "Ebola," they think of one virus. In reality, there are several species of ebolavirus, and they're about as interchangeable as a house cat and a mountain lion. The strain dominating headlines for the past decade, Zaire ebolavirus, has approved vaccines (Merck's Ervebo) and treatments (Regeneron's Inmazeb). Bundibugyo? It has neither.
That's not for lack of danger. Bundibugyo ebolavirus has a case fatality rate between 25% and 50%, depending on the outbreak and how you count. Lower than Zaire's worst outbreaks, sure. But "lower than Zaire Ebola" is a bit like saying a Category 3 hurricane is milder than a Category 5. You still don't want to be in its path.
Before 2026, the world had only seen Bundibugyo twice: Uganda in 2007 (roughly 149 cases, 37 deaths) and DRC in 2012 (about 57 cases, 29 deaths). Those were small, rural, and quickly contained. This time is different.
The Outbreak That Won't Quit
The current Bundibugyo outbreak in DRC is the largest ever recorded for this strain. As of early July 2026, the CDC reports 1,792 confirmed cases and 625 deaths in the DRC alone, with another 20 confirmed cases in Uganda. WHO declared it a "Public Health Emergency of International Concern" back in May 2026, a designation the organization doesn't hand out casually.
Cases have spread across multiple provinces: Ituri, Nord-Kivu, and Sud-Kivu in the DRC, plus Uganda's capital Kampala. At least four healthcare workers are among the dead. A case was even imported to France in late June 2026.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Dr. Stafford's infection adds the United States to the list of countries directly affected, even if his positive test came on Congolese soil. The CDC confirmed the case and is now working with his employer, DRC health authorities, and other federal agencies on contact tracing and risk assessment.
Why Ervebo Can't Save the Day
If you're wondering why health officials don't just use the existing Ebola vaccine, the answer comes down to biology. Ervebo was designed around the Zaire ebolavirus glycoprotein (the protein on the virus's surface that the immune system learns to recognize). Bundibugyo's glycoprotein is different enough that Ervebo's protection doesn't reliably transfer.
Studies of vaccinated humans tell a sobering story. People who received Ervebo did produce some antibodies that recognized the Bundibugyo glycoprotein, but those antibody levels were roughly 10x or more lower than their Zaire-specific responses. Without a known "magic number" of antibodies needed for protection, nobody can say whether that reduced response would actually keep someone alive.
WHO's official position: don't use Ervebo for Bundibugyo outbreaks outside of controlled research settings. The same applies to approved treatments like Inmazeb and Ebanga, both built for Zaire. Against Bundibugyo, they're essentially untested.
Enter Mapp Biopharma and the Experimental Arsenal
With no approved options, HHS is reaching for the best experimental tools on the shelf. The headliner: MBP134, a two-antibody cocktail from Mapp Biopharmaceutical.
Think of MBP134 as a Swiss Army knife compared to ZMapp's (Mapp's older product) single-blade pocketknife. ZMapp only recognized Zaire ebolavirus. MBP134 was designed from the start to neutralize multiple ebolavirus species, including Bundibugyo. In animal studies, it protected primates against Bundibugyo infection. In humans? That's what everyone is racing to find out.
WHO and partners have launched a clinical trial enrolling over 1,000 Bundibugyo-infected patients in the DRC. The study is testing MBP134 alone and in combination with remdesivir (Gilead's antiviral, which found fame during COVID). Patient enrollment began on July 2nd, 2026. Results could reshape how the world responds to non-Zaire Ebola outbreaks.
Separately, HHS has committed $45 million to push another experimental monoclonal antibody through Phase 1 safety trials.
The Vaccine Race Nobody Expected
On the vaccine front, multiple candidates are sprinting toward the clinic:
IAVI is developing a single-dose rVSV vaccine built specifically around the Bundibugyo glycoprotein. WHO calls it "the most promising" prophylactic candidate, but production needs 7 to 9 months to reach trial-ready quantities.
Oxford and Serum Institute have an adenovirus-based candidate (same platform family as the Oxford/AstraZeneca COVID shot) that could have doses ready for trials within 2 to 3 months.
Oxford and Moderna reportedly have candidates that could enter Phase 1 as early as mid-2026, with field trials potentially following within months after that.
BARDA, the biodefense arm of HHS, is funding these efforts through its Rapid Response Partnership Vehicle, focusing particularly on VSV-based platforms. The NETEC/ASPR NSPS STAND Award is simultaneously expanding special pathogen treatment capacity to 54 facilities across 28 states and U.S. territories, and the government is investing in glass vial production (up to 140 million additional vials annually) so that when a vaccine does work, there's actually a way to bottle and ship it.
What This Means for the Rest of Us
Let's be clear: the CDC says the risk to the American public is very low. Ebola spreads through direct contact with bodily fluids, not through the air or casual contact. The U.S. has imposed entry restrictions on non-U.S. passport holders who've been in DRC, Uganda, or South Sudan within the past 21 days. Enhanced traveler screening is in place at ports of entry.
But "low risk to Americans" misses the bigger picture. Nearly 1,800 people in the DRC have been diagnosed. Over 600 are dead. Healthcare workers are dying in a region with limited medical infrastructure, and the one American doctor we know about had to be evacuated to another continent for treatment.
The uncomfortable truth exposed by Dr. Stafford's case is that the world spent years building an Ebola toolkit optimized for one strain. When a different strain showed up at scale, the cupboard was mostly bare. HHS, WHO, and a handful of biotechs are now scrambling to fill it, but vaccines take months, trials take longer, and people are dying now.
The race against Bundibugyo isn't just a biodefense story. It's a test of whether pandemic preparedness can extend beyond the last crisis we fought.
Clinical & Regulatory
4 min read
The Drug That Worked Perfectly and Still Failed
AstraZeneca and Ionis' gene-silencing drug eplontersen did everything right biologically in a massive ATTR cardiomyopathy trial, yet still failed to keep patients alive or out of the hospital. The reason why could reshape how the entire industry thinks about combination therapy.
